- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03253367
Phenomics and Genomics of Clozapine Pharmacotherapy (CLOZIN)
Phenomics and Genomics in Clozapine Pharmacotherapy: Current, Former and New Clozapine Users
Study Overview
Status
Intervention / Treatment
Detailed Description
Rationale Clozapine (CLZ) is generally prescribed if at least two trials of antipsychotic agents have not led to satisfactory clinical improvement, thereby implying that patients on CLZ generally suffer from more severe and/or persistent symptoms than patients suffering from schizophrenia spectrum disorders (SCZ) on other antipsychotic agents. Unraveling the (functional) genetic variation underlying this severe SCZ phenotype therefore has the potential to deepen our understanding of the biological underpinnings of SCZ beyond the boundaries of DSM-based consensus criteria. Such knowledge in turn has the potential to shape future pharmacotherapeutic research. The investigators here hypothesize that targeting this phenotype in genome-wide association studies and next-generation sequencing studies will signal genetic risk loci implicated in this severe SCZ phenotype. In the future, this may lead to early detection of severe SCZ, which in turn will enable tailoring of pharmacotherapeutic strategies to such SCZ subtypes. The results of this genetic part of the study will be combined with the results from our other research protocol ('Phenomics and genomic of clozapine pharmacotherapy - New Users').The overarching goal of both projects is to create a prediction model for clozapine outcome (response (and side effects). This model includes genetic, epigenetic and clinical data.
Objectives
Primary:
1) To predict CLZ efficacy and ADRs (=treatment outcome) based on phenotypic and genetic data obtained in this study.
Secondary:
- To investigate which non-genetic factors, methylation and gene expression levels/patterns predict treatment outcome after initiating CLZ;
- As the genetic architecture of SCZ has not been fully elucidated, the current project will aid in the further elucidation of the genetic architecture of SCZ and any possible differences between 'regular' SCZ patients (those not considered treatment resistant) and those on CLZ (considered generally to be a more homogeneous and severe group).
Study design This is a mostly cross-sectional study, in which both phenotypic and genotypic data are gathered from this study population that currently uses CLZ or has used CLZ in the past. A genome-wide association study (GWAS) will be performed to reveal possible differences in genetic architecture between patients who use or have used CLZ and the broad schizophrenia phenotype on the one hand and between those who use or have used CLZ and healthy controls on the other. Targeted next-generation sequencing may be used to follow-up possible positive associations. The genetic data will be used to analyse which genetic variants are associated with CLZ response and/or side effects.
Study population The investigators will include 2,500 patients diagnosed with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS (together referred to as SCZ) >18 years of age who are currently on CLZ treatment or have used CLZ in the past. Publicly available Psychiatric Genomics Consortium (PGC) GWAS data will be used for comparisons with the broad schizophrenia phenotype group. For the purpose of the case-control comparison, the 2,500 subjects who use or have used CLZ will be age and sex-matched to 30,000 healthy control subjects for whom genotype data are available in-house.
Intervention No intervention will be applied.
Main study parameters/endpoints
- To assess whether the genetic architecture of this severe SCZ phenotype differs from the broad DSM-based SCZ phenotype.
- To predict clozapine response and side effects based on phenotypic and genetic data obtained in this study.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness Almost all patients on CLZ regularly have their blood drawn for routine white blood cell counts and/or CLZ blood level assessments. The investigators anticipate that the majority of the study population will consist of such patients as white blood cell monitoring is strictly enforced in clinical practice for this patient group. For these patients, no additional risks will be attached to the study, as the blood necessary for DNA extraction for the current study will be drawn during these routinely performed venipunctures. Time investment will also be low as the patients will only undergo a 10-minute interview. A minority of patients on CLZ does not have their blood routinely monitored and neither do patients who have used CLZ in the past. These subjects will be asked to allow a single blood draw. A venipuncture entails the risk of a hematoma (blood leaving the vessel). The investigators aim to minimize this risk by only allowing experienced personnel to draw blood and in the event of deeply located or thin veins request central lab personnel to perform the venipuncture. Although a hematoma resulting from a traumatic puncture imposes an esthetical burden on the subject, no serious health risks are involved.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Marte van der Horst, Drs.
- Phone Number: +31 0887551460
- Email: mzvanderhorst@gmail.com
Study Contact Backup
- Name: Jurjen Luykx, PhD
- Phone Number: +31 0887568638
- Email: j.luykx@umcutrecht.nl
Study Locations
-
-
-
Innsbruck, Austria, 6020
- Recruiting
- Medical University Innsbruck
-
Contact:
- Monika Edlinger, MD
- Email: monika.edlinger@i-med.ac.at
-
-
-
-
-
Kuopio, Finland, 70240
- Recruiting
- Niuvanniemen hospital
-
Contact:
- Jari Tiihonen, Prof.
-
-
-
-
-
Berlin, Germany, 10117
- Recruiting
- Charite Universitatsmedizin Berlin
-
Contact:
- Stefanie Schreiter, MD
- Phone Number: 004930450517009
- Email: stefanie.schreiter@charite.de
-
Contact:
- Stefan Gutwinski, MD
- Phone Number: 004930450517009
- Email: stefan.gutwinski@charite.de
-
-
Munich
-
München, Munich, Germany, 80336
- Recruiting
- LMU Munich
-
Contact:
- Alkomiet Hasan, MD, PhD
-
-
-
-
-
Utrecht, Netherlands, 3508 GA
- Recruiting
- UMC Utrecht
-
Contact:
- Marte van der Horst, Drs.
- Phone Number: +31 0887551460
- Email: c.pfeifer@umcutrecht.nl
-
Utrecht, Netherlands, 3512 PK
- Terminated
- Altrecht
-
-
Limburg
-
Venray, Limburg, Netherlands, 5803 AC
- Withdrawn
- Vincent van Gogh Institute
-
-
Noord-Brabant
-
's-Hertogenbosch, Noord-Brabant, Netherlands, 5211 LJ
- Recruiting
- Reinier van Arkel
-
Contact:
- Koen Grootens, MD
-
-
Noord-Holland
-
Heerhugowaard, Noord-Holland, Netherlands, 1703 WC
- Terminated
- GGZ-NHN
-
-
Oegstgeest
-
Leiden, Oegstgeest, Netherlands, 2342 EJ
- Enrolling by invitation
- GGZ Rivierduinen
-
-
Zuid Holland
-
Barendrecht, Zuid Holland, Netherlands, 2994 GC
- Terminated
- Yulius
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- he/she currently uses CLZ or he/she has used CLZ in the past/will use CLZ
- he/she has received a diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS.
- his/her age must be ≥18 years old
- he/she must be able to speak and read the language of the Informed Consent (differs per country)
- he/she must be mentally competent and have decisional capacity with regard to a decision to participate in the current study
Exclusion Criteria:
- admission to a psychiatric unit involuntarily (not all countries)
- a history of Parkinson's disease
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Current/former clozapine users
This group has only one visit.
|
|
New clozapine users
This group will be followed for 6 months prospectively.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predict clozapine response.
Time Frame: 2016-2021
|
To predict clozapine response based on phenotypic information from our questionnaire (CGI + CRES) and genetic information from GWAS
|
2016-2021
|
Predict side effects from clozapine use
Time Frame: 2016-2021
|
To predict clozapine response based on phenotypic information from our questionnaire (LUNSERS) and genetic information from GWAS
|
2016-2021
|
Assess differences in genetic architecture (GWAS)
Time Frame: 2016-2021
|
To assess whether the genetic architecture of this severe SCZ phenotype differs from the broad DSM-based SCZ phenotype.
this will be done by comparing the gentic material of clozapine users vs. non-clozapine users.
Only the clozapine DNA has to be collected yet.
|
2016-2021
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detect genetic associations (GWAS) Detect genetic associations current severe SCZ phenotype
Time Frame: 2016-2021
|
To detect genetic associations with the current severe SCZ phenotype by performing a case-control comparison with healthy participants (GWAS).
|
2016-2021
|
Increase or decrease cardiovascular disease?
Time Frame: 2016-2031
|
To investigate whether CLZ use increases or decreases the risk of cardiovascular disease and early death.
This is done by following the patients for 10 years and see whether they developed serious cardiovascular diseases
|
2016-2031
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABR: 52726 & 52728
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia Spectrum and Other Psychotic Disorders
-
VA Office of Research and DevelopmentCompletedSchizophrenia Spectrum & Other Psychotic DisordersUnited States
-
New York State Psychiatric InstituteTemple University; The Zucker Hillside Hospital; Feinstein Institutes for Medical...Not yet recruitingSchizophrenia | Schizoaffective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic Disorder
-
University of North Carolina, Chapel HillNorth Carolina Department of Health and Human ServicesCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
Laval UniversityCompletedSchizophrenia and Schizophrenia Spectrum PsychosisCanada
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified Schizophrenia Spectrum and Other Psychotic Disorder | Brief Psychotic DisorderUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Unspecified Schizophrenia Spectrum and Other Psychotic Disorder | Brief Psychotic DisorderUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH)RecruitingSchizophrenia | Schizo Affective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
Psychiatric Hospital of the University of BaselActive, not recruitingHarm Reduction | Schizophrenia and Other Psychotic DisordersSwitzerland
-
University of California, San DiegoNational Alliance for Research on Schizophrenia and DepressionCompletedSchizophrenia | Schizoaffective Disorder | Other Primary Psychotic DisordersUnited States
-
Stanford UniversityCompletedPsychotic Disorders | Schizophrenia Spectrum DisordersUnited States
Clinical Trials on Blood is obtained, mostly during routine venipuncture
-
St. Jude Children's Research HospitalCompletedLymphoma | Solid Tumor | Brain TumorUnited States
-
Duke UniversityCompletedOverweight, Obesity, Small for Gestational Age, PrematurityUnited States
-
Medical Centre LeeuwardenCompleted
-
Hospices Civils de LyonCompleted
-
Klinik für Kardiologie, Pneumologie und AngiologieCompleted
-
City of Hope Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Icahn...Recruiting
-
Ziekenhuis Oost-LimburgMaastricht UniversityCompleted
-
Institute for Clinical and Experimental MedicineNot yet recruitingHeart Failure | Pulmonary Hypertension | Pulmonary Vascular Resistance AbnormalityCzechia
-
Centre Hospitalier de CayenneUniversity Hospital, Montpellier; Direction Générale de l'Offre de Soins; Hospital...RecruitingHepatitis B, Chronic | AdultsFrench Guiana
-
Centre Hospitalier de CayenneEuropean Regional Development FundRecruitingChildren | Dengue Fever | AdultsFrance